European Heart Journal Advance Access originally published online on December 6, 2004
European Heart Journal 2005 26(3):226-233; doi:10.1093/eurheartj/ehi058
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
European Heart Journal vol. 26 no. 3 © The European Society of Cardiology 2004; all rights reserved.
Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure
1Catholic University, Department of Gerontology, Geriatrics, and Physiatrics, L.go F. Vito, I–00168 Rome, Italy
2Sticht Center on Aging, Department of Internal Medicine, Wake Forest University, Winston Salem, NC, USA
Received 22 June 2004; revised 20 October 2004; accepted 28 October 2004; online publish-ahead-of-print 6 December 2004.
* Corresponding author. Tel: +39 06 305 1190; fax: +39 06 305 1911. E-mail address: giuseppe_zuccala{at}rm.unicatt.it
Aims Cognitive dysfunction is a prevalent condition among patients with heart failure, and is independently associated with disability and mortality. Angiotensin-converting enzyme (ACE)-inhibitors might increase cerebral blood flow in subjects with heart failure. Our aim was to assess whether starting treatment with ACE-inhibitors might improve cognition in patients with heart failure.
Methods and results Analyses involved 12 081 subjects, 1220 of whom had a verified diagnosis of heart failure, enrolled in a multi-centre pharmaco-epidemiology survey. None of these participants received ACE-inhibitors before hospitalization. Among participants with heart failure, cognitive performance improved in 30% of 446 participants who started ACE-inhibitors, but only in 22% of remaining patients (P=0.001). Among participants without heart failure, cognition improved in 19% of those receiving ACE-inhibitors, and in 18% of untreated patients (P=0.765). Use of ACE-inhibitors among patients with heart failure was associated with improving cognition (odds ratio=1.57; 95% CI 1.18–2.08) also in the multivariable regression modelling, independently of baseline or discharge blood pressure levels. The probability of improving cognitive performance was higher for dosages above the median values, as compared with lower doses (odds ratios=1.90 and 1.42; P for trend=0.001), and increased with duration of treatment (odds ratios for the lower, middle, and upper tertiles=1.25, 1.34, and 1.59; P for trend=0.007).
Conclusion Treatment with ACE-inhibitors might selectively improve cognitive performance in patients with heart failure. However, up-titration of these agents might be required to yield the greatest benefit.
Key Words: Heart failure • Angiotensin-converting enzyme inhibitors • Vascular dementia • Epidemiology
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. M. Hajjar, M. Keown, P. Lewis, and A. Almor Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study American Journal of Alzheimer's Disease and Other Dementias, March 1, 2008; 23(1): 77 - 83. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L.C. Vogels, P. Scheltens, J. M. Schroeder-Tanka, and H. C. Weinstein Cognitive impairment in heart failure: A systematic review of the literature Eur J Heart Fail, May 1, 2007; 9(5): 440 - 449. [Abstract] [Full Text] [PDF]
|
|